Poland· PL-100353617
Pregabalin Accord
A pregabalin product containing pregabalinum, registered in Poland by Accord Healthcare S.L.U.. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Pregabalin is registered in 16 of 19 countries.
Countries holding a registration under ATC N02BF02 (pregabalin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Pregabalin · ATC N02BF02
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pregabalin costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), the median price runs from $0.25 in United States to $2.99 in Switzerland — a ×12 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Pregabalin · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$2.99
- IT Italy$1.59
- US United States$0.25 (acquisition cost)
The record
At a glance
URPL (Poland)- Active substance
- Pregabalinum
- Manufacturer
- Accord Healthcare S.L.U.
- Country
- Poland (PL)
- ATC code
- N02BF02
- ATC class
- Pregabalin
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05055565721100
- gtin05055565721117
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
244 interactions on record for pregabalin.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pregabalin · interactions on record
244 records
- 4 severe
- 60 moderate
- 180 info
Most severe, free to view
- MorphineN02AA01severe
- MorphinN07BC09severe
- HydrocodoneR05DA03severe
- CodeineR05DA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2397c518-3eb6-4536-b8c9-c2246b51e009 GET /v1/drugs/2397c518-3eb6-4536-b8c9-c2246b51e009?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "300 mg",
"packaging": "05055565721100 ¦ Rp ¦ EU/1/15/1027/078 ¦ 110889\n14 kaps.\nRp ¦ EU/1/15/1027/079 ¦ 110890\n21 kaps.\nRp ¦ EU/1/15/1027/087 ¦ 110891\n30 kaps.\n05055565721117 ¦ Rp ¦ EU/1/15/1027/080 ¦ 110892\n56 kaps.\nRp ¦ EU/1/15/1027/081 ¦ 110893\n60 kaps.\nRp ¦ EU/1/15/1027/082 ¦ 110894\n84 kaps.\nRp ¦ EU/1/15/1027/083 ¦ 110895\n90 kaps.\nRp ¦ EU/1/15/1027/084 ¦ 110896\n100 kaps. w blistrze\nRp ¦ EU/1/15/1027/086 ¦ 110897\n100 kaps. w blistrze perforowanym\nRp ¦ EU/1/15/1027/085 ¦ 110898\n112 kaps.\nRp ¦ EU/1/15/1027/088 ¦ 110899\n200 kaps.",
"substance": "Pregabalinum 300 mg",
"common_name": "Pregabalinum",
"pl_product_id": "100353617",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about pregabalin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.